AIHealthcare

Inductive Bio is a New York-based AI drug-discovery company developing collaborative virtual chemistry labs and machine-learning models for small-molecule compound optimization. Its platform focuses particularly on predicting and improving Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties, enabling biopharmaceutical researchers to evaluate chemical compounds before synthesis and accelerate the progression from initial molecules to lead and development candidates. The company also describes its approach as using a pre-competitive data consortium and chemical-intelligence tools spanning medicinal chemistry, computational chemistry, DMPK, and safety workflows. Its market position is as a specialized AI-enabled drug-discovery and ADMET-optimization platform for pharmaceutical and biotechnology companies; publicly reported competitive-performance claims include wins in independent ADMET prediction challenges, but these claims are not independently quantified here.